When a patient is diagnosed with amyloidosis, the care of that patient often brings in a multifaceted and multidisciplinary type of involvement of medical experts from various sectors within the healthcare profession in order to provide advice and treatment (if possible) of the various organs effected by the deposit of the amyloid protein.
As such, when the heart gets effected by the transthyretin or TTR, this condition is known as ATTR cardiomyopathy. In the recent talk organised by the UK ATTR Patient Association, Professor Julian Gilmore Clinical Lead at the National Amyloidosis Centre London speaks on,
- What does all the amyloidosis medical jargon mean?
- What is the epidemiology (the study, distribution and determinants) of cardiac amyloidosis (ATTR-CM)?
- What are the advances in diagnosis & staging of ATTR-CM?
- What are the management & treatment of ATTR amyloidosis?
- How does the advancement in treatment look like?
- What are the upcoming therapies & trials available for patients?